• Protagonist Therapeutics director William D. Waddill sold 9,000 common shares at USD 99.64 on May 29, 2026.
• Sale followed a 9,000-share option exercise at USD 11.8, lifting his direct holdings to 16,825 shares before the sale.
• Waddill ended the day with 7,825 common shares, held directly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-069047), on June 01, 2026, and is solely responsible for the information contained therein.